Winrevair (sotatercept)
Q2 2026 sales $588M, up 75%; the fastest-growing large Merck drug.
The numbers
What it is
Sotatercept, a treatment for pulmonary arterial hypertension, marketed in the US and other markets. Its growth is one of the main offsets to Gardasil's decline.
Why it matters to the stock. Winrevair is the strongest non-Keytruda growth driver and a test of whether Merck can build a second large cardiopulmonary franchise.
News
FDA adds HYPERION data to Winrevair label for newly diagnosed pulmonary arterial hypertension
The FDA approved an updated Winrevair (sotatercept) label that adds Phase 3 HYPERION data for adults newly diagnosed with pulmonary arterial hypertension who are at intermediate to high risk of progression.
Merck Q2 2026 sales rise 5% to $16.6B; 2026 EPS guidance cut to $2.66-2.76 on acquisition charges
Merck reported second-quarter 2026 sales of $16.61 billion, up 5% (4% excluding FX), with Keytruda and Keytruda Qlex at $8.37 billion.
Merck Q1 2026 sales rise 5% to $16.3B; non-GAAP loss of $1.28 per share after Cidara charge; guidance raised
Merck reported first-quarter 2026 sales of $16.3 billion, up 5% (3% excluding currency), with Keytruda and Keytruda Qlex at $8.0 billion, up 12%.